Northern Trust Corp Acorda Therapeutics Inc Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.55 - $1.0 $7,148 - $12,997	12,997 Added 49.76%	39,114 $23,000
Q4 2022 Feb 13, 2023	SELL	$0.52 - $0.77 $0 - $0	-1 Reduced -0.0%	26,117 $20,000
Q2 2022 Aug 12, 2022	SELL	$0.3 - $1.67 $153 - $851	-510 Reduced 1.92%	26,118 $12,000
Q1 2022 May 13, 2022	BUY	$1.61 - $2.5 $821 - $1,275	510 Added 1.95%	26,628 $43,000
Q4 2021 Feb 08, 2022	SELL	$2.3 - $4.71 $1,138 - $2,331	-495 Reduced 1.86%	26,118 $62,000
Q3 2021 Nov 15, 2021	SELL	$3.36 - $4.79 $8,695 - $12,396	-2,588 Reduced 8.86%	26,613 $123,000
Q2 2021 Aug 13, 2021	SELL	$3.61 - $5.23 $1,086 - $1,574	-301 Reduced 1.02%	29,201 $140,000
Q1 2021 May 12, 2021	BUY	$3.8 - $8.04 $112,107 - $237,196	29,502 New	29,502 $144,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.